Phase 2 study of dose-intense temozolomide in recurrent glioblastoma (Q33406808)

26 July 2017

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma (English)

1 reference

26 July 2017

0 references

1 reference

20

Myrna R Rosenfeld

1 reference

26 July 2017

21

Patrick Y Wen

1 reference

26 July 2017

6

Eudocia Q Lee

1 reference

26 July 2017

13

Alona Muzikansky

1 reference

26 July 2017

12

Rameen Beroukhim

1 reference

26 July 2017

4

Keith L Ligon

1 reference

26 July 2017

7

David R Reardon

1 reference

26 July 2017

1

Andrew D Norden

1 reference

26 July 2017

10

Tracy T Batchelor

1 reference

26 July 2017

3

Jan Drappatz

1 reference

26 July 2017

Katrina Smith Korfmacher

16

object named as

Katrina Smith

1 reference

26 July 2017

2

Glenn J Lesser

1 reference

26 July 2017

8

Camilo E Fadul

1 reference

26 July 2017

9

Scott R Plotkin

1 reference

26 July 2017

15

Debra Lafrankie

1 reference

26 July 2017

Samantha N Hammond

5

1 reference

26 July 2017

Jay-Jiguang Zhu

11

1 reference

26 July 2017

Lisa Doherty

14

1 reference

26 July 2017

Vida Tafoya

17

1 reference

26 July 2017

Rosina Lis

18

1 reference

26 July 2017

Edward C Stack

19

1 reference

26 July 2017

3 April 2013

1 reference

26 July 2017

1 reference

26 July 2017

15

1 reference

26 July 2017

7

1 reference

26 July 2017

930-935

1 reference

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Malignant gliomas in adults

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

The role of DNA mismatch repair in drug resistance.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3688016

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT040

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT040

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT040

21 January 2018

Identifiers

DOI

10.1093/NEUONC/NOT040

1 reference

26 July 2017

1 reference

26 July 2017

1 reference